BERLIN (dpa-AFX) - Esperion Therapeutics, Inc. (ESPR) and Daiichi Sankyo
Europe GmbH or DSE, the European arm of Japanese pharmaceutical company Daiichi
Sankyo Co., Ltd. (DSKYF.PK), announced Wednesday a $125 million amendment to
their collaboration, which includes an amicable resolution to their commercial
dispute and certain other adjustments to enhance the long-term value of their
products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an
anticipated Type II(a) variation approval by the European Medicines Agency (EMA)
for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe)
Tablet.

DSE will make an additional $25 million payment to Esperion in the calendar
quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern
District of New York will be dismissed.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the
eligible patient population and unlock its potential for cardiovascular risk
reduction. The partnership continues to grow, with DSE recently gaining
approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX